Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MT 300: Phase III data; under review in U.S

A subset analysis of patients with severe disease from the double-blind U.S.

Read the full 128 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE